KEGG   DRUG: Busulfan
Entry
D00248                      Drug                                   
Name
Busulfan (JP18/USP/INN);
Myleran (TN)
Product
BUSULFEX (Otsuka America Pharmaceutical), MYLERAN (Waylis Therapeutics LLC), MYLERAN (Woodward Pharma Services LLC)
  Generic
BUSULFAN (Accord Healthcare), BUSULFAN (Amneal Pharmaceuticals LLC), BUSULFAN (Armas Pharmaceuticals), BUSULFAN (CELLTRION USA), BUSULFAN (Hospira), BUSULFAN (Meitheal Pharmaceuticals), BUSULFAN (Meitheal Pharmaceuticals), BUSULFAN (Mylan Institutional LLC), BUSULFAN (Nexus Pharmaceuticals LLC), BUSULFAN (Pharmascience), BUSULFAN (Sagent Pharmaceuticals)
Formula
C6H14O6S2
Exact mass
246.0232
Mol weight
246.3018
Structure
Simcomp
Class
Antineoplastic
 DG01677  Alkylating agent
  DG01721  Methanesulfonate derivative
Remark
Same as: C06862
Therapeutic category: 4213
ATC code: L01AB01
Product: D00248<JP/US>
Efficacy
Antineoplastic, Alkylating agent, Immunosuppressant
  Disease
Chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia [DS:H00004]
Comment
Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome.
Target
DNA
Interaction
Structure map
map07040  Antineoplastics - alkylating agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01A ALKYLATING AGENTS
    L01AB Alkyl sulfonates
     L01AB01 Busulfan
      D00248  Busulfan (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Alkylating Agents
   Busulfan
    D00248  Busulfan (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   421  Alkylating agents
    4213  Sulfonate esters
     D00248  Busulfan (JP18/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01677  Alkylating agent
   DG01721  Methanesulfonate derivative
    D00248  Busulfan
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D00248  Busulfan
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D00248
Other DBs
CAS: 55-98-1
PubChem: 7847314
ChEBI: 28901
LigandBox: D00248
NIKKAJI: J2.316G
KCF data

ATOM        14
            1   S4a S    16.2149  -21.9100
            2   O2a O    17.4273  -22.6100
            3   C1b C    18.6397  -21.9100
            4   C1b C    19.8522  -22.6100
            5   C1b C    21.0646  -21.9100
            6   C1b C    22.2770  -22.6100
            7   O2a O    23.4895  -21.9100
            8   S4a S    24.7019  -22.6100
            9   C1a C    15.0024  -21.2100
            10  O3c O    16.9209  -20.6867
            11  O3c O    15.5214  -23.1115
            12  C1a C    25.9144  -23.3100
            13  O3c O    25.4243  -21.4059
            14  O3c O    23.9838  -23.8069
BOND        13
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     6   7 1
            7     7   8 1
            8     1   9 1
            9     1  10 2
            10    1  11 2
            11    8  12 1
            12    8  13 2
            13    8  14 2

» Japanese version   » Back

  All links  
Ontology (6)   
   KEGG BRITE (6)   
Pathway (1)   
   KEGG PATHWAY (1)   
Disease (14)   
   KEGG DISEASE (14)   
Drug (3)   
   KEGG DGROUP (1)   
   LigandBox (1)   
   SIDER (1)   
Chemical substance (6)   
   KEGG COMPOUND (1)   
   PubChem (1)   
   ChEBI (1)   
   HMDB (1)   
   HSDB (1)   
   NIKKAJI (1)   
All databases (30)   

Download RDF
DBGET integrated database retrieval system